Lv2
150 积分 2024-03-11 加入
Response and Resistance to RAS Inhibition in Cancer
1天前
已完结
Recent advances in targeted degradation in the RAS pathway
1天前
已完结
“Undruggable KRAS”: druggable after all
1天前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
1天前
已完结
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
2个月前
已完结
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
4个月前
已完结
Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors
8个月前
已完结
Characterization of a Potential Animal Model of an Idiosyncratic Drug Reaction: Nevirapine-Induced Skin Rash in the Rat
9个月前
已完结
Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC
10个月前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
10个月前
已完结
Particle engineering enabled by polyphenol-mediated supramolecular networks
皖公网安备34019202002308
